Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer

被引：0
|
作者：
Thomas Kuehr
Paul Ruff
Bernardo L Rapoport
Stephen Falk
Francis Daniel
Conrad Jacobs
Neville Davidson
Josef Thaler
Blandine Boussard
James Carmichael
机构：
[1] Hospital Barmherzige Schwestern vom heiligen Kreuz,Department of Medical Oncology
[2] Johannesburg Hospital,Plymouth Oncology Centre
[3] The Medical Oncology Centre of Rosebank,East Cape Oncology Centre
[4] Bristol Oncology Centre,Oncology Suite
[5] Derriford Hospital,Cancer Research Campaign Department of Clinical Oncology
[6] St George's Hospital,undefined
[7] Broomfield Hospital,undefined
[8] Global Medical Affairs Oncology,undefined
[9] City Hospital,undefined
来源：
BMC Cancer | / 4卷
关键词：
Neutropenia; Dose Level; Irinotecan; Febrile Neutropenia; Maximum Tolerate Dose;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer
    Aranda, E
    Carrato, A
    Cervantes, A
    Sastre, J
    Gómez, MA
    Abad, A
    Masutti, B
    Ribera, F
    Marcuello, E
    Pronk, L
    Balcells, M
    Díaz-Rubio, E
    ANNALS OF ONCOLOGY, 2004, 15 (04) : 559 - 567
  • [32] Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis
    Liang Xiao-bo
    Hou Sheng-huai
    Li Yao-ping
    Wang Li-chun
    Zhang Xin
    Yang Jun
    CHINESE MEDICAL JOURNAL, 2010, 123 (22) : 3314 - 3318
  • [33] Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer
    Vanhoefer, U
    Harstrick, A
    Köhne, CH
    Achterrath, W
    Rustum, YM
    Seeber, S
    Wilke, H
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) : 907 - 913
  • [34] A phase I/II of CPT-11 combined with 5-fluorouracil (5FU)/folinic acid (FA) Nordic schedule as first line therapy in patients (pts) with metastatic colorectal cancer (MCRC).
    Ristamaki, R
    Glimelius, B
    Linne, T
    Pfeiffer, P
    Kjaer, M
    Skovsgaard, T
    Boussard, B
    Oulid-Aissa, D
    Pyrhönen, S
    ANNALS OF ONCOLOGY, 2000, 11 : 47 - 47
  • [35] Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer
    Andreas Teufel
    Silke Steinmann
    Jürgen Siebler
    Christiane Zanke
    Herbert Hohl
    Bernd Adami
    M Schroeder
    O Klein
    Thomas Höhler
    Peter R Galle
    Michael Heike
    Markus Moehler
    BMC Cancer, 4
  • [36] Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer
    Gerard, B
    Bleiberg, H
    Van Daele, D
    Gil, T
    Hendlisz, A
    Di Leo, A
    Fernez, B
    Brienza, S
    ANTI-CANCER DRUGS, 1998, 9 (04) : 301 - 305
  • [37] Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial
    Santini, D.
    Graziano, F.
    Catalano, V.
    Di Seri, M.
    Testa, E.
    Baldelli, A. M.
    Giordani, P.
    La Cesa, A.
    Spalletta, B.
    Vincenzi, B.
    Russo, A.
    Caraglia, M.
    Virzi, V.
    Cascinu, S.
    Tonini, G.
    BMC CANCER, 2006, 6 (1)
  • [38] Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial
    D Santini
    F Graziano
    V Catalano
    M Di Seri
    E Testa
    AM Baldelli
    P Giordani
    A La Cesa
    B Spalletta
    B Vincenzi
    A Russo
    M Caraglia
    V Virzi
    S Cascinu
    G Tonini
    BMC Cancer, 6
  • [39] A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients
    De Vita, F
    Orditura, M
    Matano, E
    Bianco, R
    Carlomagno, C
    Infusino, S
    Damiano, V
    Simeone, E
    Diadema, MR
    Lieto, E
    Castellano, P
    Pepe, S
    De Placido, S
    Galizia, G
    Di Martino, N
    Ciardiello, F
    Catalano, G
    Bianco, AR
    BRITISH JOURNAL OF CANCER, 2005, 92 (09) : 1644 - 1649
  • [40] FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC):: a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)
    Souglakos, J
    Androulakis, N
    Syrigos, K
    Polyzos, A
    Ziras, N
    Athanasiadis, A
    Kakolyris, S
    Tsousis, S
    Kouroussis, C
    Vamvakas, L
    Kalykaki, A
    Samonis, G
    Mavroudis, D
    Georgoulias, V
    BRITISH JOURNAL OF CANCER, 2006, 94 (06) : 798 - 805
12345